Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas

Author(s):  Choo Winnie

Issue:  Jul/Aug 2017 - Volume 21, Number 4
View All Articles in Issue

Page(s):  282-289

Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 1
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 2
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 3
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 4
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 5
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 6
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 7
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Page 8

Download in electronic PDF format for $75

Abstract:  The discovery of beta-adrenergic blocker effects on infantile hemangiomas has affected the choice of treatment in recent years. Oral propranolol is effective in treating infantile hemangiomas, but the risk of systemic side effects remains a concern. Data from literature review reported positive clinical outcomes with no major adverse effects observed in children using topical beta-blocker such as timolol maleate. Topical application of timolol eye drop has been mentioned in few studies, most of which reported that the solution cannot stay on the site of application due to its fluidity. Adding hydroxyethyl cellulose into a timolol solution increased its viscosity by forming a hydrogel and thus changed the rheology property. The compounded timolol gel exhibited thixotropy property allowing better and longer contact at sites of application. Experimental data from literature review showed desirable characteristics and measurable flux of timolol across human stratum corneum. Gel dosage form allows easy and precise application and maximizes timolol’s therapeutic efficacy at the sites of application.

Related Keywords: infantile hemangioma, strawberry birthmark, beta-adrenergic antagonists, beta blockers, timolol maleate, topical preparation, infants, children, formulation, timolol eye drops, 2-hydroxyethyl cellulose, transdermal permeability, skin permeation, stability, sterility, microbial contamination

Related Categories: DERMATOLOGY, FORMULATIONS, PEDIATRICS, ADVERSE DRUG EVENTS, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas
Choo Winnie
Jul/Aug 2017
Pg. 282-289

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

Timolol 0.125%/Mucolox 15%/0.9% Normal Saline Nasal Spray
Allen Loyd V Jr
Mar/Apr 2023
Pg. 153

Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride
Zur Eyal
Sep/Oct 2011
Pg. 358-366

Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution
Allen Loyd V Jr
Mar/Apr 2018
Pg. 147

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Mixon William
, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2009
Pg. 506-515

Basics of Compounding for Disorders of the External Ear
Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48

Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation
Robert Marie-Claude
, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Sep/Oct 2014
Pg. 418-426

Measurement of Free Iodine in Different Formulations of Povidone-Iodine Eye Drops 5%
Berisa Prado Silvia
, Riestra Ayora Ana Cristina, Trelles Campa Adrián
Sep/Oct 2019
Pg. 418-421

Basics of Compounding: Compounding Irrigation Solutions for Sterile and Nonsterile Preparations
Allen Loyd V Jr
Nov/Dec 2017
Pg. 481-486

A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
Nov/Dec 2022
Pg. 480-488

Addendum to Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine A New Therapeutic Modality
Mar/Apr 2024
Pg. 129

Quality-Control Analytical Methods: Applications and Sterility of Autologous Eye Drops
Reed-Kane Dana
, Carlson Rachel A, Kupiec Thomas C, Vu Nicole
Nov/Dec 2009
Pg. 540-543

Acute Migraine Treatment with Timolol 0.5% Nasal Spray - Compounding Pharmacists Have an Important Role
Hagan John C III
, Kosa Steven C, Chamberlain Tyler
Jul/Aug 2024
Pg. 286-290

Current Trends and Emerging Priorities in Compounded Preparations for Children
Parrish Richard H II
Sep/Oct 2018
Pg. 358-366

Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Allen Loyd V Jr
Sep/Oct 2016
Pg. 399-404

Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
May/Jun 2016
Pg. 247-249

Return to Top